← Back to Clinical Trials
RecruitingPhase 4NCT06431477

Efficacy and Safety of Telmisartan Compared With Losartan

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionDiabetic Nephropathies
SponsorChong Kun Dang Pharmaceutical
Study TypeINTERVENTIONAL
PhasePhase 4
Enrollment98
SexALL
Min Age19 Years
Max Age75 Years
Start Date2023-04-19
Completion2025-10-31
Interventions
telmisartanLosartan

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

A study to evaluate the efficacy and safety of telmisartan compared with losartan in patients with diabetic nephropathy and hypertension

Eligibility Criteria

Inclusion Criteria: * Male of Female subjects aged ≥19 or \<75 * Type II Diabetes Mellitus subjects who have been taken medicine * Subjects who have voluntarily decided to participate in this clinical trial and Signed ICF Exclusion Criteria: * Subjects with Type I Diabetes Mellitus * Subjects with Primary hyper-aldosteronism * Subjects with a history of drug or alcohol abuse or suspected patient within 1 year as of the time of screening * Pregnant women, lactating women, or subjects who do not agree to use appropriate contraception during the clinical trial period * Subjects who received other clinical trial drugs within 28 days of screening visit * Subjects who are unable to participate in this clinical trial at the discretion of the investigator.

Related Trials